Logo image of JANX

JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis

USA - NASDAQ:JANX - US47103J1051 - Common Stock

26.76 USD
-0.44 (-1.62%)
Last: 10/17/2025, 8:21:56 PM
26.5 USD
-0.26 (-0.97%)
After Hours: 10/17/2025, 8:21:56 PM
Fundamental Rating

4

JANX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability. JANX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year JANX has reported negative net income.
JANX had a negative operating cash flow in the past year.
JANX had negative earnings in each of the past 5 years.
JANX had a negative operating cash flow in each of the past 5 years.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

JANX has a better Return On Assets (-10.23%) than 83.74% of its industry peers.
JANX's Return On Equity of -10.67% is amongst the best of the industry. JANX outperforms 88.22% of its industry peers.
Industry RankSector Rank
ROA -10.23%
ROE -10.67%
ROIC N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JANX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, JANX has more shares outstanding
JANX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

JANX has an Altman-Z score of 23.42. This indicates that JANX is financially healthy and has little risk of bankruptcy at the moment.
JANX has a better Altman-Z score (23.42) than 91.78% of its industry peers.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.42
ROIC/WACCN/A
WACC9.35%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 47.03 indicates that JANX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 47.03, JANX belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
A Quick Ratio of 47.03 indicates that JANX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 47.03, JANX belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 47.03
Quick Ratio 47.03
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for JANX have decreased strongly by -97.80% in the last year.
JANX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.10%.
Measured over the past years, JANX shows a very strong growth in Revenue. The Revenue has been growing by 42.75% on average per year.
EPS 1Y (TTM)-97.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, JANX will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.34% on average per year.
Based on estimates for the next years, JANX will show a very strong growth in Revenue. The Revenue will grow by 77.61% on average per year.
EPS Next Y-81.29%
EPS Next 2Y-55.15%
EPS Next 3Y-43.43%
EPS Next 5Y-17.34%
Revenue Next Year-74.19%
Revenue Next 2Y-29.66%
Revenue Next 3Y-21.01%
Revenue Next 5Y77.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as JANX's earnings are expected to decrease with -43.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-55.15%
EPS Next 3Y-43.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JANX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JANUX THERAPEUTICS INC

NASDAQ:JANX (10/17/2025, 8:21:56 PM)

After market: 26.5 -0.26 (-0.97%)

26.76

-0.44 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners107.51%
Inst Owner Change-0.02%
Ins Owners1.45%
Ins Owner Change1.05%
Market Cap1.61B
Analysts86.96
Price Target79.97 (198.84%)
Short Float %15.22%
Short Ratio11.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5%
Min EPS beat(2)-15.55%
Max EPS beat(2)5.55%
EPS beat(4)2
Avg EPS beat(4)-10.02%
Min EPS beat(4)-52.65%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)15.29%
EPS beat(12)10
Avg EPS beat(12)16.66%
EPS beat(16)11
Avg EPS beat(16)9.8%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-93.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)-73.78%
Revenue beat(8)4
Avg Revenue beat(8)142.73%
Revenue beat(12)8
Avg Revenue beat(12)145.86%
Revenue beat(16)12
Avg Revenue beat(16)189.67%
PT rev (1m)0%
PT rev (3m)-6.16%
EPS NQ rev (1m)-1.44%
EPS NQ rev (3m)-14.53%
EPS NY rev (1m)1.19%
EPS NY rev (3m)-11.07%
Revenue NQ rev (1m)17.14%
Revenue NQ rev (3m)1461.83%
Revenue NY rev (1m)23.79%
Revenue NY rev (3m)542.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3662.89
P/FCF N/A
P/OCF N/A
P/B 1.62
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.01
BVpS16.48
TBVpS16.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.23%
ROE -10.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.76%
Cap/Sales 207.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 47.03
Quick Ratio 47.03
Altman-Z 23.42
F-Score2
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)293.31%
Cap/Depr(5y)445.07%
Cap/Sales(3y)33.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-81.29%
EPS Next 2Y-55.15%
EPS Next 3Y-43.43%
EPS Next 5Y-17.34%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-74.19%
Revenue Next 2Y-29.66%
Revenue Next 3Y-21.01%
Revenue Next 5Y77.61%
EBIT growth 1Y-119.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.01%
EBIT Next 3Y-39.39%
EBIT Next 5Y-20.63%
FCF growth 1Y-1.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.14%
OCF growth 3YN/A
OCF growth 5YN/A